MetaCap

Context Therapeutics (CNTX) vs Quoin Pharmaceuticals (QNRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quoin Pharmaceuticals (QNRX) has outperformed Context Therapeutics (CNTX) over the past year, losing 82.1% versus a loss of 85.3%. Over five years, CNTX leads with a -96.9% price change compared with -100.0% for QNRX. Quoin Pharmaceuticals is the larger company by market cap ($15.8 million vs $14.7 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNTX-85.32%QNRX-82.07%
+223%+61%-100%
Nov 21, 20251 yearNov 20, 2026
CNTX-96.73%QNRX-99.99%
+16%-45%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNTX versus QNRX key metrics
MetricCNTXQNRX
Share price$0.16$3.28
Market cap$14.70M$15.76M
1-day change-5.10%-2.35%
YTD return-89.12%-77.27%
1-year return-85.32%-82.07%
5-year return-96.86%-99.99%
P/E ratio (TTM)—7.45
EPS (TTM)$-0.46$0.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-36.12M$-15.80M
52-week high$3.62$23.50
52-week low$0.153$3.18
Distance from 52-week high-95.58%-86.04%
Analyst consensusnonenone
Avg. price target upside+2418.75%+565.55%
Average volume1.42M541.26K
Shares outstanding91.88M4.80M
Employees154
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Context Therapeutics

CNTX stock →

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

About Quoin Pharmaceuticals

QNRX stock →

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

CNTX vs QNRX FAQ

Which is bigger, Context Therapeutics or Quoin Pharmaceuticals?

Quoin Pharmaceuticals (QNRX) is larger, with a market capitalization of $15.76M compared with $14.70M for Context Therapeutics (CNTX).

Which stock has performed better over the past year, CNTX or QNRX?

QNRX returned -82.07% over the past 12 months, compared with -85.32% for CNTX (price return, excluding dividends). Past performance does not predict future results.

Are Context Therapeutics and Quoin Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons